title: Tyrosine kinase inhibitors and epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer: to test or not to test?
authors.affiliation: From Hamon Center for Therapeutic Oncology Research and Department of Pathology, University of Texas Southwestern Medical Center, Dallas, Texas.
authors.forename: Adi F
authors.initials: AF
authors.lastname: Gazdar
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000208:ethnology / Q000235:genetics; D000069347:Erlotinib Hydrochloride; D000077156:Gefitinib; D018773:Genes, erbB-1 / Q000235:genetics*; D005820:Genetic Testing; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000208:ethnology / Q000235:genetics; D009154:Mutation / Q000235:genetics*; D010597:Pharmacogenetics; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors*; D011799:Quinazolines / Q000627:therapeutic use; D013624:Taiwan; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D011799:Quinazolines; D000069347:Erlotinib Hydrochloride; D011505:Protein-Tyrosine Kinases; D000077156:Gefitinib